NCT04703686 2026-03-16
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
The Lymphoma Academic Research Organisation
Phase 2 Completed
The Lymphoma Academic Research Organisation
The Lymphoma Academic Research Organisation
Nantes University Hospital
University of California, Davis
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute